首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Advanced Drug Delivery Reviews

Advanced Drug Delivery Reviews杂志,由Elsevier出版,于1987年创刊,Monthly,出版语言English,ISSN:0169-409X,E-ISSN:1872-8294。

投稿咨询
Advanced Drug Delivery Reviews
Advanced Drug Delivery Reviews
Advanced Drug Delivery Reviews
SCI SCIE EI

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
21
CiteScore
39
期刊收录
SCI、SCIE、EI

Advanced Drug Delivery Reviews(中文译名:《先进的药物输送审查》),ISSN:0169-409X,EISSN:1872-8294,是Elsevier出版的国际性学术期刊,创刊于1987年,以Monthly形式稳定发行,2026年总发文量约126篇。该刊采用非OA开放访问,学科归属为医学 - 药学。该刊是医学、药学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)、EI(工程索引)等国际主流学术数据库收录。2026年期刊影响因子达21,2025年期刊CiteScore为39,2025年期刊自引率约1.4%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Advanced Drug Delivery Reviews长期聚焦医学、药学及相关产业的技术应用前沿,平均审稿周期一般,3-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、药学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、Australia、England、GERMANY (FED REP GER)、France、Netherlands等为核心发文国家与地区;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)HARVARD UNIVERSITY、UNIVERSITY OF CALIFORNIA SYSTEM、UNIVERSITY OF NORTH CAROLINA、UNIVERSITY OF SYDNEY、JOHNS HOPKINS UNIVERSITY、UNIVERSITY OF TEXAS SYSTEM等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
PHARMACOLOGY & PHARMACY 药学
1区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
PHARMACOLOGY & PHARMACY 药学
1区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
PHARMACOLOGY & PHARMACY 药学
1区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q1 4 / 356

99

学科:PHARMACOLOGY & PHARMACY SCIE Q1 9 / 356

97.61

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q1 4 / 352

99

学科:PHARMACOLOGY & PHARMACY SCIE Q1 8 / 353

97.88


中国学者近期发文

1
Self-assembled Nano-PROTACs: bridging chemical design and biological barriers in targeted protein degradatio

Author:Zhang, Ni-Yuan; Liang, Jian-Xiao; Hu, Bei-Ning; Wang, Yi; An, Hong-Wei; Wang, Hao

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2026; Vol. 234, Issue , pp. -. DOI: 10.1016/j.addr.2026.115861

2
Pharmacokinetic modeling to optimize development and therapeutic potential of mAb-based therapie

Author:Fan, Xiaoqing; Chen, Chengcong; Zhang, Lin; Cao, Kangna; Yan, Xiaoyu

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2026; Vol. 233, Issue , pp. -. DOI: 10.1016/j.addr.2026.115850

3
NanoTAC in targeted protein degradation: Intelligent delivery platforms and synergistic therapeutic paradigm

Author:Qian, Jieying; Duan, Hongtao; Zheng, Qingqi; Yang, Yuzhao; Huang, Xiaowan; Shi, Bingyang; Zhang, Yunjiao

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2026; Vol. 232, Issue , pp. -. DOI: 10.1016/j.addr.2026.115821

4
Stimuli-responsive nanodiamonds for precision pharmacokinetics, pharmacodynamics, and drug delivery application

Author:Zare, Iman; Jafari, Mansour; Nasab, Shima Zahed; Farani, Marzieh Ramezani; Rahi, Amid; Ghaee, Azadeh; Shourangiz-Haghighi, Alireza; Nik, Amirala Bakhshian; Zhang, Mingzhen; Kang, Heemin; Dabiri, Shahriar; Afshar, Reza Malekpour; Patel, Savan K.; Mitchell, Michael M.; Schirhagl, Romana; Najafabadi, Alireza Hassani

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2026; Vol. 232, Issue , pp. -. DOI: 10.1016/j.addr.2026.115822

5
Strategies for targeted protein degradation through lysosomal pathway

Author:Wang, Wei; Fang, Yuxin; Sheng, Chunquan

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2026; Vol. 232, Issue , pp. -. DOI: 10.1016/j.addr.2026.115837

6
Nanodrug delivery systems in tumor immunotherapy: From immune activation to tumor reprogrammin

Author:Mao, Dengxuan; Li, Bingqian; Li, Jing; Pan, Jianquan; Wu, Zimei; Feng, Nianping

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2026; Vol. 232, Issue , pp. -. DOI: 10.1016/j.addr.2026.115838

7
Stimuli-activatable protein degraders for targeted cancer therapy: from prodrug design to nanoplatform application

Author:Jiang, Xingyu; Chen, Yinuo; Gao, Yunna; Rong, Rui; Lai, Yi; Zhu, Zheying; Xu, Zhiai

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2026; Vol. 232, Issue , pp. -. DOI: 10.1016/j.addr.2026.115808

8
Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular diseas

Author:Zhu, Shuqian; Zhang, Jianjun; Jiang, Xuling; Peng, Cheng; Liu, Huiqin; Qian, Feng

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2026; Vol. 230, Issue , pp. -. DOI: 10.1016/j.addr.2026.115773

9
Covalent chemistry in targeted protein degradatio

Author:Tan, Jing; Liang, Yuxin; Shao, Shiqun; Shen, Youqing

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2026; Vol. 230, Issue , pp. -. DOI: 10.1016/j.addr.2026.115777

10
Harnessing targeted protein degradation to potentiate cancer immunotherapy: from molecular mechanisms to delivery strategie

Author:Liu, Ye; Ullah, Ihsan; Yuan, Youyong; Wang, Jun

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2026; Vol. 230, Issue , pp. -. DOI: 10.1016/j.addr.2026.115776


在线咨询

Advanced Drug Delivery Reviews

国际简称:ADV DRUG DELIVER REV参考译名:先进的药物输送审查

年发文量:126 CiteScore:39 是否预警:否 Gold OA文章占比:30.83% 研究类文章占比:0.00%

杂志社联系方式:ELSEVIER SCIENCE BV, PO BOX 211, AMSTERDAM, NETHERLANDS, 1000 AE

Advanced Drug Delivery Reviews